Table of Contents
Leukemia Research and Treatment
Volume 2011, Article ID 592519, 3 pages
http://dx.doi.org/10.4061/2011/592519
Case Report

A Rare t(9;22;16)(q34;q11;q24) Translocation in Chronic Myeloid Leukemia for Which Imatinib Mesylate Was Effective: A Case Report

1Department of Hematology, Osaka City General Hospital, 2-13-22 Miyakojimahondori, Miyakojima-Ku, Osaka 534-0021, Japan
2Department of Hematology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-Ku, Osaka 545-8585, Japan
3Department of Pathology, Osaka City General Hospital, 2-13-22 Miyakojimahondori, Miyakojima-Ku, Osaka 534-0021, Japan

Received 15 February 2011; Revised 20 April 2011; Accepted 15 May 2011

Academic Editor: Daniela Cilloni

Copyright © 2011 Masahiro Manabe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Johansson, T. Fioretos, and F. Mitelman, “Cytogenetic and molecular genetic evolution of chronic myeloid leukemia,” Acta Haematologica, vol. 107, no. 2, pp. 76–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Mitelman, B. Johansson, and F. Mertens, Eds., “Mitelman database of chromosome aberrations in cancer,” February 2011, http://www.cgap.nci.nih.gov/Chromosomes/Mitelman.
  3. M. Sumi, T. Tauchi, G. Sashida et al., “Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients,” Clinical and Laboratory Haematology, vol. 27, no. 6, pp. 416–417, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Stagno, P. Vigneri, V. D. Fabro et al., “Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors,” Acta Oncologica, vol. 49, no. 4, pp. 506–508, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Bernstein, M. R. Pinto, and C. Wallace, “The incidence, type, and subsequent evolution of 14 variant Ph1 translocations in 180 South African patients with Ph1-positive chronic myeloid leukemia,” Cancer Genetics and Cytogenetics, vol. 12, no. 3, pp. 225–238, 1984. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Dube, J. Dixon, T. Beckett et al., “Location of breakpoint within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes,” Genes Chromosomes and Cancer, vol. 1, no. 1, pp. 106–111, 1989. View at Google Scholar · View at Scopus
  7. T. Ishihara and M. Minamihisamatsu, “The Philadelphia chromosome. Considerations based on studies of variant Ph translocations,” Cancer Genetics and Cytogenetics, vol. 32, no. 1, pp. 75–92, 1988. View at Google Scholar · View at Scopus
  8. J. P. M. Espinoza, V. J. P. Cárdenas, E. A. V. Jiménez, M. G. Angulo, M. A. E. Flores, and J. R. G. García, “A complex translocation (9;22;16)(q34;q11.2;p13) in chronic myelocytic leukemia,” Cancer Genetics and Cytogenetics, vol. 157, no. 2, pp. 175–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. G. Reid, B. J. P. Huntly, C. Grace, A. R. Green, and E. P. Nacheva, “Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia,” British Journal of Haematology, vol. 121, no. 3, pp. 419–427, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Hagemeijer, C. R. Bartram, and E. M. E. Smit, “Is the chromosomal region 9q34 always involved in variants of the Ph1 translocation?” Cancer Genetics and Cytogenetics, vol. 13, no. 1, pp. 1–16, 1984. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Richebourg, V. Eclache, C. Perot et al., “Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy,” Cancer Genetics and Cytogenetics, vol. 182, no. 2, pp. 95–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Morel, A. Herry, M. J. Le Bris et al., “Contribution of fluorescence in situ hybridization analyses to the characterization of masked and complex Philadelphia chromosome translocations in chronic myelocytic leukemia,” Cancer Genetics and Cytogenetics, vol. 147, no. 2, pp. 115–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Gorusu, P. Benn, Z. Li, and M. Fang, “On the genesis and prognosis of variant translocations in chronic myeloid leukemia,” Cancer Genetics and Cytogenetics, vol. 173, no. 2, pp. 97–106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. T. El-Zimaity, H. Kantarjian, M. Talpaz et al., “Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome,” British Journal of Haematology, vol. 125, no. 2, pp. 187–195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Marzocchi, F. Castagnetti, and S. Luatti, “Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis,” Blood, vol. 117, no. 25, pp. 6793–6800, 2011. View at Google Scholar